Core Points - Biophytis SA is participating in the 15th International Conference on Frailty and Sarcopenia Research (ICFSR) from March 12 to 14 in Toulouse, focusing on age-related diseases [1][2] - The ICFSR is a significant annual event aimed at advancing clinical trials for frail older adults, featuring rigorous peer-reviewed research published in the Journal of Frailty and Aging [2] - Biophytis will present preliminary data on its lead drug candidate BIO101, which targets muscle preservation in obese patients treated with GLP-1 receptor agonists [3] Company Overview - Biophytis SA is a clinical-stage biotechnology company developing drug candidates for age-related diseases, with its lead candidate BIO101 in Phase 3 for sarcopenia and Phase 1-2 for Duchenne muscular dystrophy [3] - The company also has completed Phase 2-3 trials for COVID-19 and is preparing to start Phase 2 trials for obesity [3] - Biophytis is headquartered in Paris, France, with subsidiaries in Cambridge, Massachusetts, and Brazil, and its shares are listed on Euronext Growth Paris and OTC market [3]
Biophytis Announces its Participation in the 15th International Conference on Frailty and Sarcopenia Research (ICFSR)